On June 26, 2024, Ying Du, Chairperson & CEO of Zai Lab Ltd (ZLAB, Financial), executed a sale of 23,939 shares of the company, according to the SEC Filing. Following this transaction, the insider now directly owns 1,142,833 shares in the company.
Zai Lab Ltd (ZLAB, Financial) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for cancer, autoimmune, and infectious diseases. The company aims to address significant unmet medical needs for patients around the globe.
Over the past year, Ying Du has sold a total of 38,106 shares of Zai Lab Ltd and has not made any purchases of the stock. This recent transaction is part of a broader trend observed within the company, where there have been 21 insider sells and only 3 insider buys over the past year.
Shares of Zai Lab Ltd were trading at $17.9 on the day of the transaction. The company currently holds a market cap of approximately $1.769 billion.
The stock's valuation metrics show a price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow based on historical trading multiples and adjusted factors reflecting the company's past performance and expected future business outcomes.
According to the GF Value, the intrinsic value of Zai Lab Ltd's stock is estimated at $57.71, which suggests that the stock is currently undervalued with a price-to-GF-Value ratio of 0.31. This valuation indicates a "Possible Value Trap, Think Twice" scenario, urging potential investors to carefully consider the stock.
This insider selling activity and the current valuation metrics provide critical data points for investors monitoring Zai Lab Ltd's stock performance and insider behaviors.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
